1 GGNet Mental Health Care Center, Apeldoorn, the Netherlands.
2 Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
J Psychopharmacol. 2018 Mar;32(3):353-356. doi: 10.1177/0269881117735684. Epub 2017 Oct 17.
Cannabis use disorders are frequently comorbid in patients with a psychotic disorder and are associated with worse outcomes. To date there are no proven effective strategies to achieve cannabis abstinence in this population. An alternative for abstinence might be harm reduction, i.e. replacing the use of street cannabis with high tetrahydrocannabinol and low cannabidiol levels by medicinal cannabis variants with relatively low tetrahydrocannabinol and relatively high cannabidiol levels, thereby reducing the psychosis inducing effects of cannabis and enhancing the antipsychotic effects of cannabis. Here we present the data of a case series with seven inpatients diagnosed with a psychotic disorder and a treatment-resistant cannabis use disorder who received substitution therapy with a low tetrahydrocannabinol medicinal cannabis variant (Bedrolite). The results suggest that the low tetrahydrocannabinol medicinal cannabis variant Bedrolite is not effective in the treatment of inpatients with a psychotic disorder and comorbid cannabis use disorder. Bedrolite is thus not very likely to become an effective harm reduction strategy in these patients.
大麻使用障碍在精神障碍患者中经常并发，并且与更差的结果相关。迄今为止，对于该人群，还没有被证实有效的实现大麻戒除的策略。戒除的替代方法可能是减少伤害，即通过使用四氢大麻酚和低大麻二酚含量相对较低的药用大麻变体代替街头大麻，同时具有相对较低的四氢大麻酚和相对较高的大麻二酚水平，从而降低大麻诱导精神障碍的效果，并增强大麻的抗精神病作用。在这里，我们呈现了一项有 7 名住院患者的病例系列数据，这些患者被诊断患有精神障碍和治疗抵抗性大麻使用障碍，并接受了低四氢大麻酚药用大麻变体（Bedrolite）的替代治疗。结果表明，低四氢大麻酚药用大麻变体 Bedrolite 对于治疗伴有精神障碍和共病大麻使用障碍的住院患者无效。因此，Bedrolite 不太可能成为这些患者有效的减少伤害策略。
